Table 1 Clinical data and deletion 13q pattern of 68 CLL cases with isolated del 13q
From: Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
Frequency | Percent | |
|---|---|---|
Gender | ||
Female | 28 | 41 |
Male | 40 | 59 |
RAI stage | ||
Low (0, 1, 2) | 46 | 70 |
High (4, 5) | 14 | 20 |
Treatment | ||
Positive | 23 | 33 |
Negative | 41 | 60 |
Beta2 microglobulin | ||
< 3.5 | 18 | 55 |
> 3.5 | 15 | 45 |
RB1 deletion | ||
Positive | 27 | 40 |
Negative | 41 | 60 |
13q deletion rate | ||
< 80% | 52 | 77 |
> 80% | 16 | 23 |
< 70% | 46 | 68 |
> 70% | 22 | 32 |
< 60% | 40 | 59 |
> 60% | 28 | 41 |
Deletion type | ||
Monoallelic | 58 | 96 |
Biallelic | 2 | 4 |